Intrabony Periodontal Defect, Periodontal Attachment Loss, Periodontal Diseases, Pocket, Periodontal
Conditions
Keywords
rhPDGF, Growth factors, Periodontal regeneration, L-PRF, Enamel Matrix Derivatives
Brief summary
The aim of the present study is to clinically and radiographically compare the efficacy of recombinant human platelet-derived growth factor (rhPDGF), Leukocyte-Platelet Rich Fibrin (L-PRF) and Enamel Matrix Derivatives (EMD) in intrabony defects following minimally invasive non surgical peridoontal therapy (MINST). This study will be designed as a randomized clinical trial of 12-month duration. A total of 88 patients (each with a single infrabony defect) will be recruited and randomly equally distributed into 4 groups: an experimental group treated with MINST and rhPDGF, a second group treated with MINST + L-PRF, a third group treated with MINST and EMD and and a control group treated with MINST alone. Each defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following MINST experimental and control sites will be randomly chosen. The test sites will be treated by inserting a collagen plug soaked for at least 15 minutes in a 1.5cc solution containing hPDGF-BB. In the second group the infrabony defects will be treated with MINST and L-PRF. In the third group the infrabony defects will be treated with MINST and EMD. The control group will be treated with MINST alone. Pre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing. Standardized radiographs of selected study sites will be taken at baseline and at the 6 and 12 months follow-up visits using the long-cone technique with a customized holder and a thermoplastic occlusal reference to allow reproducible positioning. All radiographs will be analysed by a dedicated dental software (Carestream Dental LLC Atlanta, GA, USA) to make linear measurements. The defect bone level (DBL), the defect angle (DA), the intra- and suprabony components of the defect and the radiographic defect area (RDA) will be evaluated.
Interventions
PROCEDURESRP+rhPDGF
The infrabony defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in rhPDGF.
PROCEDURESRP+L-PRF
The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of a L-PRF membrane.
PROCEDUREMINST alone
The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
PROCEDUREMINST+EMD
The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of EMD gel.
Sponsors
G. d'Annunzio University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of periodontitis stage III or IV (grades A to C), * non-smokers or former smokers who quit at least 1 year ago, and * had not received any periodontal treatment in the 3 months prior to recruitment; * Presence of at least 1 Infrabony defect (PPD ≥ 5 mm with infrabony defect depth of ≥3mm at screening radiograph); * One and two wall infrabony defects at screening radiograph and periodontal charting. * Signed informed consent.
Exclusion criteria
* Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C\>7%, rheumatoid arthritis or any form of immunosuppression; * Subjects requiring antibiotic prophylaxis; * 3-wall infrabony defects; * Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment; * Presence of furcation defect; * Chronic intake of NSAIDs or steroids, currently; * Patients undergoing orthodontic treatment, having removable prosthetic appliances, pregnancy, tumors of the oral cavity or the presence of any psychiatric condition that could affect participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Defect Bone Level (DBL) | 12 months | Distance between the cemento-enamel junction (CEJ) and the bottom of the defect (BD) |
| Clinical Attachment Level (CAL) | 12 months | Distance between the CEJ and the bottom of the pocket |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pocket Probing Depth (PPD) | 12 months | Distance between the gingival margin and the bottom of the pocket. |
| Gingival Recession (GR) | 12 months | Distance between the CEJ and the gingival margin. |
| Defect Angle (DA) | 12 months | Angle between the long axis of the tooth and the interproximal wall of the infrabony defect. |
| Radiographic Defect Area | 12 months | Area of the triangle defined by: side passing through the top of the interproximal ridge and perpendicular to the long axis of the tooth, side passing through the bottom of the defect and the intersection of the previous side with the root of the tooth, side passing through the top of the ridge and the bottom of the defect. |
Countries
Albania
Contacts
CONTACTMichele Paolantonio, DDS, MD
STUDY_CHAIRMichele Paolantonio, DDS, MD
University 'G. D'Annunzio' of Chieti
Outcome results
None listed